Biotec Services International Ltd   Report issue

For profit Phase 3
Founded: Bridgend United Kingdom (1997)
Status: Acquired by PCI Pharma Services (2014)

Organization Overview

First Clinical Trial
2012
NCT01297959
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

riboflavin (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2